MSCI Nordic Index Rises 0.5% to 401.41, Highest Close Since Sept 8

The index's move to a multi-month high is being carried by a single name rather than broad participation, and that concentration is the real story: Genmab's 29% surge is far larger than the headline index gain, meaning the aggregate number understates both the strength in one stock and the drag elsewhere. Healthcare's leadership among the ten sectors reinforces that this was a sector-specific, company-driven session rather than a rotation across Nordic markets. The open question is whether Genmab's re-rating holds and whether healthcare leadership broadens beyond it, or whether the index gives back the gain once the single-stock catalyst fades.